Drugs & Targets Dragonfly Therapeutics, BMS agree to exclusive global license for IL-12 investigational immunotherapy program September 04, 2020Vol.46 No.33
Drugs & Targets Thermo Fisher Scientific, Hengrui Therapeutics to develop companion diagnostic in NSCLC indication September 04, 2020Vol.46 No.33
Drugs & TargetsFree Tecentriq approved by FDA for BRAF V600 unresectable or metastatic melanoma July 31, 2020Vol.46 No.31
Drugs & TargetsFree FDA approves first cell-based gene therapy for adult patients with relapsed or refractory MCL July 31, 2020Vol.46 No.31
Drugs & TargetsFree Keytruda receives two sBLA acceptances from FDA in TNBC in indications July 31, 2020Vol.46 No.31
Drugs & TargetsFree HIF-2α inhibitor MK-6482 receives FDA Breakthrough Designation for Von Hippel-Lindau Disease-associated RCC July 31, 2020Vol.46 No.31
Drugs & TargetsFree Engineered macrophage immunotherapy receives IND clearance from FDA July 31, 2020Vol.46 No.31
Drugs & TargetsFree BDTX-189 receives FDA Fast Track Designation for solid tumors harboring HER2 or EGFR mutations July 31, 2020Vol.46 No.31
Drugs & TargetsFree Tagrisso receives FDA Breakthrough Therapy Designation for adjuvant treatment of stage IB-IIIA EGFR-mutated lung cancer July 31, 2020Vol.46 No.31
Drugs & TargetsFree Piqray receives approval in Europe for HR+/HER2- advanced breast cancer with a PIK3CA mutation July 31, 2020Vol.46 No.31
